Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck And Cipla Bury Differences To Co-market Raltegravir In India

This article was originally published in PharmAsia News

Executive Summary

Merck agreed to co-market its patented HIV product raltegravir in India with rival Cipla, bringing to end what had started as an attempt for a voluntary license and could have veered toward a compulsory license.

You may also be interested in...

ViiV Healthcare Questions Natco's Ability To Make And Sell Selzentry In India; Stays Silent On Voluntary License Issue

MUMBAI - ViiV Healthcare - formed by GlaxoSmithKline Pharmaceuticals Plc and Pfizer Inc. in 2009 to work on a range of HIV/AIDS medications - struck back with a volley of questions to Natco Pharma Ltd., which had sought a voluntary license in December 2010 to manufacture generic versions of Selzentry

Cipla Targets Merck's Leading Anti-HIV Brand Isentress; Applies For Voluntary License In India

MUMBAI - Merck & Co.'s HIV integrase inhibitor Isentress (raltegravir) may have been a big success across many markets, but in India the anti-AIDS drug may be short of its mark. Leading home-grown company Cipla Ltd. has taken the route of applying for a "voluntary license" for the drug to New Jersey-headquartered Merck because Cipla says it is not reaching needy patients in India and it is priced exorbitantly

Indian Court Nixes Bayer's Nexavar Patent Plea; Cipla Allowed To Market Generic Versions

MUMBAI - In a landmark decision that will further restrict multinational drug companies from introducing their internationally marketed brands in India, the Delhi High Court rejected German drug maker Bayer's plea to stop the Drug Controller General of India - the Indian drug regulator - from granting marketing approval to generic drug maker Cipla for kidney/liver cancer drug Nexavar (sorafenib)


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts